Ectromelia Virus

Overview and Taxonomy of Ectromelia Virus

Taxonomic Classification and Phylogenetic Position

Ectromelia virus (ECTV) is the etiological agent of mousepox, a severe and often fatal systemic disease of mice [1, 6]. It is classified within the genus Orthopoxvirus, family Poxviridae, subfamily Chordopoxvirinae [1, 6, 9]. The genus Orthopoxvirus includes several viruses of significant medical and veterinary importance, most notably variola virus (VARV), the causative agent of smallpox; monkeypox virus (MPXV), a zoonotic pathogen of growing public health concern; vaccinia virus (VACV), the live vaccine used for smallpox eradication; and cowpox virus (CPXV) [1, 2, 5, 17]. The phylogenetic proximity of ECTV to VARV and MPXV has been firmly established through genomic sequencing and comparative analyses, revealing that ECTV shares approximately 98.2% nucleotide sequence identity with the Moscow strain of ECTV, and similar high levels of homology with other orthopoxviruses [26, 28]. Indeed, the genome of an isolate from a human erythromelalgia-associated poxvirus (ERPV) was shown to be 99.8% identical to the Naval strain of ECTV, confirming that ERPV is in fact an ECTV strain, likely derived from a laboratory mouse source [28]. This close genetic relationship underscores the value of ECTV as a surrogate model for studying orthopoxvirus biology, pathogenesis, and the host immune response [1, 5, 32].

ECTV possesses a linear, double-stranded DNA genome approximately 200–220 kilobase pairs in length, encapsulated within a complex, brick-shaped virion [1, 2]. Like all poxviruses, ECTV replicates entirely within the host cell cytoplasm, a feature that distinguishes it from most other DNA viruses [6]. The genome encodes a multitude of proteins, including those essential for viral replication, assembly, and egress, as well as a sophisticated arsenal of immunomodulatory proteins that antagonize host antiviral defenses [2, 3, 6, 23]. The viral genome is characterized by terminal inverted repeats and a hairpin loop structure at each end, a hallmark of poxvirus genomes [26, 28].

Host Range and Species Specificity

ECTV is a rodent-specific virus, with its natural host being the mouse (Mus musculus) [1, 6, 9]. In contrast to many other orthopoxviruses, such as MPXV or CPXV, which exhibit a broad host range and can infect multiple mammalian species including humans, ECTV demonstrates a highly restricted host tropism. There is no evidence of natural human infection with ECTV, and the virus is not considered a zoonotic pathogen [6, 32]. This narrow host range is a critical feature that makes ECTV an ideal model for studying orthopoxvirus pathogenesis in a natural host, as it recapitulates the co-evolutionary relationship between a poxvirus and its specific mammalian reservoir, analogous to the relationship between VARV and humans [1, 17, 32]. The disease produced in mice, mousepox, closely mimics the progression of smallpox in humans, including a primary lesion at the site of infection, lympho-hematogenous dissemination to secondary organs (spleen and liver), and a characteristic skin rash [6, 22, 32].

The host range restriction of ECTV is not absolute, as the virus can abortively infect certain cell lines from non-murine species. For example, ECTV replicates inefficiently in rabbit RK13 cells, exhibiting a block in late gene expression and a severely blunted production of enveloped virions [24]. This abortive replication is independent of the presence of the host range genes E3L and K3L, which are known to mediate poxvirus host range in other systems, indicating that additional, unidentified factors govern the species specificity of ECTV [24].

Genomic Architecture and Key Virulence Determinants

The ECTV genome is a paradigm of poxviral genetic economy, encoding over 150 open reading frames (ORFs). Among these are a multitude of genes dedicated to subverting the host immune response, a strategy essential for viral success in a natural host [2, 3, 6, 20]. These immunomodulatory proteins include secreted cytokine and chemokine binding proteins, inhibitors of apoptosis, and antagonists of intracellular signaling pathways. A notable example is the C15 protein, a homolog of the variola virus B22 membrane protein, which functions as a virulence factor by inhibiting NK cell activation and T cell responses, thereby facilitating early viral spread from the draining lymph node to systemic sites [8, 23]. Another critical virulence factor is the viral poly(A) polymerase catalytic subunit (PAPL), which has been shown to interact with and antagonize the antiviral activity of host guanylate-binding protein 2 (GBP2), an interferon-stimulated gene that inhibits ECTV replication [2, 3].

ECTV also encodes a secreted chemokine-binding protein, E163, which binds chemokines through their glycosaminoglycan (GAG)-binding domains and prevents their interaction with cell-surface GAGs, thereby disrupting chemokine gradient formation and immune cell recruitment [18]. The epidermal growth factor ortholog, ECGF, is a potent mitogen that activates the EGF receptor, inducing S-phase entry and promoting cell proliferation, which may support viral replication in the infected tissue [11]. Additionally, ECTV possesses a functional E3L ortholog, encoding a double-stranded RNA-binding protein that is essential for viral replication by antagonizing the host protein kinase R (PKR) and RNase L pathways [15, 21]. Unlike VACV, ECTV lacks an intact K3L gene, but it compensates by accumulating lower levels of double-stranded RNA during infection, thereby evading PKR activation through a distinct mechanism [21].

Several proteins modulate the host cell cytoskeleton to facilitate viral dissemination. The A36R protein mediates actin-based motility, promoting the release of progeny virions from infected cells in vitro, although its role in vivo appears to be less critical [16]. ECTV infection also induces dramatic rearrangements of the microtubule and actin cytoskeletons in dendritic cells and macrophages, leading to the formation of long actin-based cellular protrusions that serve as "cytoplasmic corridors" for virus spread [4, 19]. The virus further alters mitochondrial network morphology and physiology, inducing fragmentation and redistribution of mitochondria around viral factories, likely to support energy requirements for replication and morphogenesis [1, 14].

Strain Diversity and Geographic Distribution

Multiple strains of ECTV have been isolated from outbreaks in laboratory mouse colonies worldwide. The most extensively studied strain is ECTV-Moscow (ECTV-Mos), which is highly virulent in susceptible mouse strains [1, 22, 26]. Other notable isolates include ECTV-Naval and ECTV-Cornell, which were recovered from separate outbreaks in the United States in 1995 and 1999, respectively [26]. Genomic comparison of these strains with ECTV-Mos revealed 98.2% nucleotide sequence identity, indicating that the Naval, Cornell, and Moscow strains are closely related but distinct [26]. Despite the genetic divergence, ECTV-Naval remains equally virulent in susceptible BALB/c mice when administered via the footpad route, demonstrating that the observed genetic differences do not impair its pathogenic potential in this model [26]. The erythromelalgia-related poxvirus (ERPV), recovered from human throat swabs in China in 1987, is now recognized as a strain of ECTV, sharing 99.8% identity with ECTV-Naval [28]. The geographic distribution of ECTV is global, with outbreaks reported in laboratory mouse facilities across Europe, North America, and Asia. The virus is not known to circulate in wild mouse populations in nature, but it can persist in laboratory colonies, where it can be transmitted through direct contact, fomites, and aerosols [6, 25].

Ectromelia Virus as a Model for Human Orthopoxvirus Disease

The importance of ECTV extends far beyond its role as a pathogen of laboratory mice. Since the eradication of smallpox and the cessation of routine vaccination in 1980, the human population has become increasingly susceptible to orthopoxvirus infections, including MPXV, which has emerged as a significant global health threat [1, 3, 5]. The "Animal Efficacy Rule" established by the United States Food and Drug Administration (FDA) permits the licensure of medical countermeasures against smallpox based on efficacy data from well-characterized animal models, given that human efficacy trials are no longer feasible [22, 32]. The mousepox model fulfills this role admirably, as it recapitulates key aspects of smallpox pathogenesis: a primary infection at the inoculation site, lympho-hematogenous spread to the reticuloendothelial system (spleen and liver), and a final cutaneous rash that parallels the exanthem of smallpox [6, 22, 32].

The availability of inbred mouse strains with differential susceptibility to ECTV provides an unparalleled opportunity to dissect the genetic and immunological determinants of resistance and susceptibility to orthopoxvirus infection. C57BL/6 mice are highly resistant to ECTV and survive infection without clinical signs, whereas BALB/c mice are exquisitely susceptible and succumb to lethal mousepox [10, 20, 29]. This difference is governed by multiple host genetic factors, including natural killer cell receptor haplotypes and major histocompatibility complex alleles, and it mirrors the variable susceptibility of human populations to smallpox [10, 12, 20]. Furthermore, the availability of congenic and gene-knockout mice allows for the systematic interrogation of specific host pathways required for antiviral defense. For instance, resistance to ECTV requires the cyclic GMP-AMP synthase (cGAS)-STING pathway in bone marrow-derived cells for type I interferon production [12, 13], and type I interferon signaling is essential in natural killer cells and monocytes but not in adaptive immune cells or parenchymal cells [10].

The mousepox model has been instrumental in evaluating the efficacy of antiviral drugs and vaccines against orthopoxviruses. Compounds such as cidofovir, brincidofovir (CMX001), and tecovirimat have demonstrated protective efficacy in ECTV-challenged mice, supporting their development as human therapeutics [6, 7, 27]. Similarly, the model has been used to test attenuated vaccinia virus strains, such as MVA and NYCBHΔE3L, for their ability to induce protective immunity against a lethal ECTV challenge [15, 30, 31]. The model has also been used to investigate the potential for virus persistence and recrudescence, revealing that ECTV can persist in the bone marrow and blood of recovered mice and can be reactivated by immunosuppression, leading to transmission to naïve co-housed animals [25]. This observation has significant implications for our understanding of orthopoxvirus latency and the potential for virus reintroduction into naïve populations.

In summary, ECTV is a phylogenetically close relative of VARV and MPXV that causes a natural, lethal disease in its murine host. Its genetic tractability, the availability of diverse mouse strains and knockout tools, and the close similarity of mousepox to human smallpox make it an indispensable model for understanding orthopoxvirus pathogenesis, immune evasion, and the development of medical countermeasures. The continued study of ECTV is critical for global health security, particularly in the context of emerging orthopoxvirus threats such as monkeypox.

Molecular Pathogenesis: Host-Virus Interactions and Mitochondrial Dynamics

The molecular pathogenesis of ectromelia virus (ECTV) is a paradigm of sophisticated host-virus co-evolution, wherein the virus has developed an arsenal of immunomodulatory proteins that systematically dismantle the host’s antiviral defenses while simultaneously hijacking cellular organelles, most notably mitochondria, to create a permissive environment for replication. This section provides an exhaustive analysis of the molecular mechanisms governing ECTV-host interactions, with a particular focus on mitochondrial dynamics, the cGAS-STING signaling axis, interferon antagonism, and the subversion of innate immune cell function.

The cGAS-STING Axis: Cytosolic DNA Sensing and Type I Interferon Induction

A cornerstone of the innate immune response to ECTV is the detection of its large double-stranded DNA genome within the host cytoplasm. The cyclic GMP-AMP synthase (cGAS) serves as the primary cytosolic DNA sensor, binding DNA and catalyzing the synthesis of the second messenger 2’3’-cGAMP. This cyclic dinucleotide subsequently activates the adaptor protein STING (stimulator of interferon genes), which translocates from the endoplasmic reticulum to perinuclear compartments, ultimately activating TANK-binding kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3) to drive type I interferon (IFN-I) production [12, 13]. Elegant studies using murine L929 fibroblasts and RAW 264.7 macrophages have demonstrated that ECTV infection robustly activates this pathway, and that disruption of cGas or Sting expression in these cells completely abrogates IFN-β induction, leading to a dramatic increase in viral replication [13]. The critical nature of this pathway is underscored by in vivo experiments: mice deficient in cGAS or STING exhibit significantly lower serum IFN-I levels, higher viral loads in the spleen and liver, and succumb rapidly to mousepox, even on the normally resistant C57BL/6 background [12, 13]. Importantly, the requirement for cGAS is cell-type specific. Using bone marrow chimeras, it was demonstrated that cGAS expression in bone marrow-derived (BMD) cells, likely including dendritic cells and macrophages, is essential for systemic IFN-I production and survival, whereas cGAS expression in non-hematopoietic cells such as hepatocytes is dispensable [12]. This finding highlights the sentinel role of myeloid cells in sensing ECTV and initiating the antiviral cascade. Remarkably, therapeutic bypass of cGAS deficiency is possible: direct administration of 2’3’-cGAMP can rescue cGAS-knockout mice from lethal infection, but this rescue fails in IRF7- or IFNAR-deficient mice, confirming that the cGAS-STING pathway operates upstream of IRF7-dependent IFN-I amplification [12]. The downstream signaling cascade involves IRF7, which is essential for the robust production of IFN-α subtypes. In the absence of IRF7, the IFN-I response is severely blunted, and mice succumb to ECTV despite intact cGAS-STING activation [12]. Thus, the molecular hierarchy, cGAS → STING → TBK1 → IRF3/IRF7 → IFN-I, represents a non-redundant pathway for resistance to ECTV.

Mitochondrial Dynamics: From Antiviral Signaling to Viral Subversion

Mitochondria are not merely passive energy suppliers during ECTV infection; they are central hubs for antiviral signaling and are actively targeted by the virus. The mitochondrial antiviral signaling protein (MAVS) is the essential adaptor for RIG-I-like receptor (RLR) signaling, but its function is intimately linked to mitochondrial network morphology. During ECTV infection, the mitochondrial network undergoes dramatic and dynamic alterations that directly modulate MAVS-dependent immunity. In permissive L929 murine fibroblasts, early infection (2-4 hours post-infection) is characterized by the perinuclear clustering of mitochondria around viral replication factories, a process that likely facilitates the localized supply of ATP and biosynthetic precursors for viral genome replication and morphogenesis [14]. As infection progresses to later stages (12-24 hours), the mitochondrial network undergoes profound fragmentation, transitioning from a filamentous, interconnected reticulum to a dispersed population of punctate, individual mitochondria [1, 14]. This fragmentation is accompanied by a loss of mitochondrial membrane potential (ΔΨm), increased reactive oxygen species (ROS) production, and altered expression of fission/fusion machinery components [14].

The functional consequences of these morphological changes are profound. A fragmented mitochondrial network is associated with impaired MAVS signaling, as MAVS aggregation on the mitochondrial outer membrane, a prerequisite for downstream IRF3 activation, is more efficient on elongated, fused mitochondria. Conversely, chemically inducing mitochondrial elongation using the Drp1 inhibitor Mdivi-1 prior to ECTV infection significantly attenuates the virus’s ability to suppress MAVS-dependent IFN-β induction, resulting in reduced viral titers [1]. In contrast, treatment with the uncoupling agent CCCP, which induces mitochondrial fragmentation, paradoxically reduces progeny virion production but also enhances the virus’s suppression of the immune response, suggesting a complex trade-off between replication efficiency and immune evasion [1]. These data indicate that ECTV actively promotes mitochondrial fragmentation as a strategy to dismantle the MAVS signaling platform, thereby blunting the RLR-mediated antiviral response.

Beyond morphology, ECTV profoundly alters the mitochondrial transcriptome. Using Ingenuity Pathway Analysis (IPA) of L929 fibroblasts and RAW 264.7 macrophages, the “Sirtuin Signaling Pathway” emerges as the most significantly modulated canonical pathway during late-stage infection [34]. Sirtuins are NAD+-dependent deacetylases that regulate mitochondrial biogenesis, energy metabolism, and stress responses. ECTV infection broadly downregulates genes involved in mitochondrial transport (e.g., Timm and Tomm family members), small molecule transport, inner membrane translocation, and membrane polarization [34]. This downregulation is cell-type specific: macrophages exhibit a more profound suppression of mitochondria-related genes compared to fibroblasts, correlating with the greater susceptibility of macrophages to ECTV-induced apoptosis [34]. Intriguingly, only L929 fibroblasts show upregulation of Slc25a23 and Slc25a31, genes encoding mitochondrial ATP-Mg/Pi carriers and adenine nucleotide translocators, respectively, suggesting that fibroblasts attempt to maintain oxidative phosphorylation and ATP production to support viral replication, whereas macrophages undergo metabolic collapse [34]. This metabolic reprogramming is further supported by the observation that ECTV-infected L929 cells upregulate the mitochondrial heat shock proteins Hsp60 and Hsp10, which localize predominantly to mitochondria and are associated with a marked reduction in apoptotic potential, as evidenced by decreased Bax levels and increased Bcl-2 and Bcl-xL expression [36]. This “mitochondrial heat shock response” likely serves to preserve mitochondrial protein homeostasis and prevent the release of cytochrome c, thereby blocking the intrinsic apoptosis pathway and ensuring a prolonged window for viral replication [36].

Interferon Antagonism and the E3L/PKR Axis

A critical determinant of ECTV host range and virulence is its ability to antagonize the double-stranded RNA (dsRNA)-activated protein kinase R (PKR) pathway. Unlike vaccinia virus (VACV), which encodes both E3L (a dsRNA-binding protein) and K3L (a pseudosubstrate inhibitor of PKR), ECTV possesses an intact E3L ortholog but lacks a functional K3L gene [15, 21]. Despite this deficiency, ECTV is remarkably efficient at evading PKR. The mechanism lies in the virus’s transcriptional economy: ECTV accumulates significantly less dsRNA during infection compared to VACV, as detected by a monoclonal antibody specific for dsRNA [21]. This reduced dsRNA burden is attributable to lower steady-state mRNA levels and reduced transcriptional read-through of certain viral genes, thereby limiting the primary ligand for PKR activation [21]. The E3L protein itself is essential for ECTV replication; a targeted deletion mutant (ECTVΔE3L) is replication-defective in all cell lines tested, exhibiting abortive late gene expression and no significant translation of late mRNAs [15]. This replication defect is completely rescued in PKR-knockout cells, confirming that the primary function of E3L is to sequester dsRNA and prevent PKR-mediated translational shutdown [15]. The importance of this axis is further underscored by the fact that ectopic expression of VACV E3 and K3 cannot rescue ECTV replication in restrictive rabbit RK13 cells, indicating that additional, unidentified host range factors limit ECTV tropism [24]. In vivo, ECTVΔE3L is completely nonpathogenic in susceptible BALB/c mice but induces robust protective immunity against wild-type challenge, highlighting the potential of E3L-deleted poxviruses as safe vaccine vectors [15, 31].

Guanylate-Binding Proteins and Viral Countermeasures

Interferon-stimulated genes (ISGs) constitute a formidable barrier to ECTV replication, and among these, the guanylate-binding proteins (GBPs) have emerged as critical effectors. GBP2 is highly upregulated in response to IFN-I during ECTV infection and exerts a dose-dependent inhibitory effect on viral replication [2]. The antiviral mechanism of GBP2 is dependent on its N-terminal GTPase activity; a GTP-binding-impaired mutant (GBP2K51A) completely loses its inhibitory capacity [2]. GBP2 appears to act at a post-entry step, as it does not affect viral attachment or early gene expression but significantly impairs late gene expression and viral morphogenesis [2]. In a classic example of host-virus molecular arms race, ECTV has evolved a specific countermeasure: the viral poly(A) polymerase catalytic subunit (PAPL). Using immunoprecipitation coupled with mass spectrometry (IP/MS) and co-immunoprecipitation, it was demonstrated that PAPL directly interacts with GBP2 [3]. This interaction leads to a reduction in GBP2 protein levels, likely through enhanced proteasomal degradation, thereby antagonizing its antiviral activity [3]. The functional significance of PAPL is underscored by the fact that a CRISPR/Cas9-mediated knockout of the PAPL gene in ECTV significantly attenuates viral replication, indicating that PAPL is an indispensable virulence factor that neutralizes the GBP2-mediated restriction [3]. This discovery positions PAPL as a potential target for antiviral intervention.

Subversion of Dendritic Cell Function and Antigen Presentation

Dendritic cells (DCs) are the sentinels of the immune system, and ECTV has evolved multiple strategies to paralyze their function. Infection of conventional DCs (cDCs) with ECTV leads to a profound downregulation of cathepsins (B, L, and S) and their endogenous inhibitors, cystatins (B and C), at both the mRNA and protein levels [35, 39]. Cathepsins are essential for the proteolytic processing of antigens within endosomal compartments, a prerequisite for loading peptides onto MHC class II molecules. The suppression of cathepsin activity results in a marked impairment of the DC’s ability to endocytose and process soluble antigens [35]. Furthermore, remnants of cathepsin L and cystatin B are observed to co-localize with viral replication centers (viral factories), suggesting that the virus may sequester these host proteins to further disrupt antigen processing [35]. The functional consequence of this suppression is a failure of ECTV-infected DCs to stimulate allogeneic CD4+ T cell proliferation in mixed leukocyte reactions (MLR) [20, 38]. This “functional paralysis” extends beyond antigen presentation; ECTV-infected DCs also fail to upregulate costimulatory molecules (CD80/86) and MHC molecules in response to TLR4 stimulation, and they exhibit a blunted proinflammatory cytokine response, with downregulation of TLR, RLR, and NLR signaling components [20, 38]. Notably, this immunosuppressive effect is mouse strain-independent, occurring equally in DCs from resistant C57BL/6 and susceptible BALB/c mice, suggesting that the virus’s capacity to disable DCs is a universal strategy [38].

Chemokine Decoys and Immune Evasion

ECTV encodes a secreted chemokine-binding protein, E163, which acts as a potent decoy receptor. E163 binds chemokines through their glycosaminoglycan (GAG)-binding domain, thereby preventing chemokine interaction with cell-surface GAGs and disrupting the formation of chemotactic gradients essential for leukocyte trafficking [18]. The protein itself is anchored to the cell surface via its own GAG-binding regions, allowing it to locally neutralize chemokines and inhibit the recruitment of inflammatory cells to the site of infection [18]. This mechanism is particularly important for limiting the influx of NK cells and monocytes into the draining lymph node, thereby blunting the early innate immune response.

The Role of NK Cells and the C15 Virulence Factor

Natural killer (NK) cells are critical for early control of ECTV, and their activation is dependent on type I interferon signaling. IFNAR expression on NK cells is essential for their cytolytic function; in the absence of IFNAR, NK cells fail to degranulate and control viral spread [10]. The recruitment of NK cells to the draining lymph node (dLN) is a complex, multi-step process that is impaired in aged mice due to defective dendritic cell migration. In young mice, migratory DCs (mDCs) traffic from the skin to the dLN, where they produce CCL2 and CCL7 to recruit inflammatory monocytes (iMOs). These mDCs also upregulate NKG2D ligands, inducing IFN-γ production by group 1 innate lymphoid cells (G1-ILCs). The IFN-γ, in turn, stimulates incoming iMOs to secrete CXCL9, which is the critical chemokine for NK cell recruitment [33]. ECTV directly antagonizes this cascade through its largest virulence factor, C15. C15 is a member of a well-conserved poxviral family that inhibits T cell activation, but it also limits contact between NK cells and infected cells in vivo, as demonstrated by quantitative immunofluorescence imaging [8]. This results in a significant reduction in the total number of degranulating NK cells, without affecting NK cell cytokine production or the transcription of factors related to NK cell recruitment [8]. The C15 protein is a key determinant of virulence; deletion of the C15 gene (ECTV-C15Stop) does not affect viral replication in vitro but dramatically attenuates virulence in vivo, with reduced viral loads in the dLN, spleen, and liver, and decreased mortality in BALB/c mice [23]. This attenuation is dependent on CD4+ and CD8+ T cells, indicating that C15 functions primarily by disabling the adaptive immune response [23].

Actin Cytoskeleton, Microtubules, and Viral Dissemination

The late stages of ECTV infection are characterized by dramatic cytoskeletal rearrangements that facilitate viral egress and cell-to-cell spread. ECTV induces the formation of long actin-based cellular protrusions, or “cytoplasmic corridors,” in infected macrophages and DCs [19]. These protrusions contain straight tubulin filaments and numerous punctate mitochondria, and they form convex structures termed “cytoplasmic packets” that are packed with progeny virions [19]. The formation of these structures is dependent on the viral protein A36, which recruits the Arp2/3 actin-nucleating complex to promote actin polymerization at the cell surface [16]. While actin-based motility is critical for virus release in vitro, its role in vivo is less pronounced; deletion of A36R impairs cell-to-cell spread but does not completely abrogate virulence, suggesting that microtubule-dependent transport provides a compensatory mechanism [16]. Indeed, ECTV infection induces a dramatic rearrangement of the microtubule (MT) cytoskeleton, characterized by the disappearance of the microtubule organizing center (MTOC) and increased α-tubulin acetylation, which stabilizes MTs and facilitates the kinesin-1-dependent transport of viral particles to the cell periphery [37]. This subversion of the cytoskeleton is accompanied by the downregulation of numerous genes involved in MT organization and dynamics [37]. Furthermore, ECTV induces spontaneous cell-cell fusion (syncytia formation) under neutral pH conditions, both in vitro and in the lungs of infected mice, a process that is not inhibited by the viral fusion inhibitory complex A56/K2 [40]. This fusion “from within” or “from without” allows the virus to spread directly between cells, evading extracellular immune surveillance.

Epidemiology and Transmission of Mousepox

The epidemiology of mousepox, caused by ectromelia virus (ECTV), is a study in contrasts: a disease of devastating lethality within naive laboratory mouse colonies, yet one that remains exquisitely restricted to a single host genus. Understanding its transmission dynamics requires a multi-layered analysis, ranging from the molecular mechanisms of viral egress and cell-to-cell spread, to the population-level factors of host genetics, environmental stability, and the capacity for long-term persistence. While ECTV is not a zoonotic agent of public health concern for humans, a critical distinction from its orthopoxvirus relatives monkeypox and variola virus, its study provides the foundational model for how a highly virulent poxvirus maintains itself within a susceptible population. The epidemiology of mousepox is therefore inseparable from the biology of its host, Mus musculus, and the conditions of laboratory husbandry.

Host Range and Reservoir Ecology

ECTV is a rodent-specific orthopoxvirus, with its natural and experimental host range confined almost exclusively to mice of the genus Mus. This strict tropism is a defining epidemiological feature [6, 9]. Unlike monkeypox virus, which has a broad host range and can circulate in multiple rodent and primate species, or cowpox virus, which is maintained in bank voles and wood mice, ECTV appears to have co-evolved specifically with the house mouse. This co-evolution is reflected in the virus’s sophisticated arsenal of host-specific immunomodulatory proteins, many of which function optimally only in murine cells. The narrow host range is further evidenced by the abortive replication of ECTV in rabbit RK13 cells, despite the virus’s possession of a functional E3L ortholog; the factors limiting its host range in non-murine cells remain incompletely understood but are not solely attributable to the absence of K3L, as seen in vaccinia virus [24].

The natural reservoir of ECTV is the mouse itself, and the virus is not known to be maintained in any other wild or domestic animal species. Outbreaks in laboratory mouse colonies are therefore typically traced back to the introduction of an infected, often subclinically shedding animal, or through contaminated biological materials such as serum, tumor lines, or cell cultures. The lack of a wildlife reservoir outside of Mus means that the virus is not enzootic in most natural environments, a fact that underpins its success as a controllable pathogen in modern research facilities. However, historical outbreaks, such as the Naval and Cornell incidents in the United States during the mid-1990s, underscore the virus's capacity for rapid, silent spread once introduced into a naive colony [26]. Phylogenetic analysis of these isolates revealed an extremely high degree of sequence identity (98.2%) with the virulent Moscow strain, confirming that even geographically and temporally distinct outbreaks are caused by genetically stable, highly virulent lineages [26]. An intriguing epidemiological footnote is the identification of an erythromelalgia-associated poxvirus (ERPV) from throat swabs of humans in China, which was subsequently sequenced and found to be 99.8% identical to the ECTV-Naval strain [28]. While this finding raises the possibility of a very rare zoonotic or laboratory-contaminant event, it does not alter the fundamental consensus that ECTV is not a naturally circulating human pathogen. The primary epidemiological relevance of ECTV remains its role as a threat to laboratory mouse colonies and as a surrogate model for smallpox research under the U.S. FDA’s "Animal Efficacy Rule" [22, 32].

Modes of Transmission: From Direct Contact to Aerosolization

The transmission of ECTV is multifaceted, reflecting the virus’s ability to exploit multiple routes of infection to ensure its propagation within a susceptible population. The principal modes include direct contact, the fecal-oral route, aerosol inhalation, and percutaneous inoculation through bites or scratches [6]. The relative importance of each route depends on the husbandry conditions, the density of the mouse population, and the stage of clinical disease in the index animal.

Direct contact and fomites are considered the most common routes of transmission in a laboratory setting. Infected mice shed high titers of virus in urine, feces, and from skin lesions. The virus is remarkably stable in the environment, capable of surviving in dried exudates and bedding for extended periods, which facilitates indirect transmission via contaminated cages, equipment, and personnel. The fecal-oral route is likely a major mechanism, as coprophagic behavior in mice leads to ingestion of infectious particles, allowing the virus to gain entry via the oral or esophageal mucosa.

Aerosol and respiratory transmission represents a particularly efficient and challenging route for disease control. Intranasal instillation of even low doses of ECTV (e.g., 125 PFU in BALB/c mice) results in rapid, lethal infection characterized by complete mortality by day 10 [22]. The virus replicates productively within the respiratory tract, and lung pathology is a hallmark of severe mousepox. Importantly, ECTV induces spontaneous cell-cell fusion (syncytia formation) in infected lung tissue, a process that occurs under neutral pH conditions in vivo and is not inhibited by the virus’s own A56/K2 fusion inhibitory complex [40]. This fusion activity likely facilitates direct cell-to-cell spread of viral genomes and progeny, bypassing the extracellular environment and humoral immune effectors, thereby accelerating dissemination within the lung parenchyma. In the context of a colony outbreak, the high density of animals and poor ventilation can rapidly establish aerosol transmission, leading to explosive spread that is difficult to contain without depopulation.

Percutaneous transmission is the route most commonly used in experimental models (footpad inoculation) and likely occurs naturally through bites, especially in the context of aggressive male mice or during fighting. This route bypasses many of the initial mucosal barriers and directly delivers virus to the dermis and underlying tissue, where it can establish a primary replication focus. From the skin, the virus must then navigate the draining lymphatics to establish systemic infection, a process that is actively facilitated by viral manipulation of the host cell cytoskeleton.

Viral Dissemination and the Role of Cellular Protrusions

The ability of ECTV to spread from the initial infection site to secondary organs and finally to the skin (the site of the classical rash and onward transmission) is dependent on its capacity to hijack the host’s cellular machinery for movement. This is not a passive process of simple diffusion; rather, ECTV actively remodels the cytoskeleton of infected cells to promote its own egress. Later stages of infection in both macrophages and dendritic cells are characterized by the formation of remarkably long, actin-based cellular extensions, termed "cytoplasmic corridors", that extend from the infected cell and contain straight tubulin filaments, numerous punctate mitochondria, and large convex structures known as "cytoplasmic packets" [19]. These packets are laden with progeny virions and represent privileged sites for viral budding and release. This actin-based motility is critical for efficient virus release in vitro, although its in vivo importance for long-range spread appears to be partially redundant with microtubule-dependent transport mechanisms [16]. Nevertheless, the induction of these protrusions provides a direct mechanism for ECTV to disseminate from infected immune cells to adjacent naive cells, facilitating local amplification of the infection even in the presence of an otherwise intact tissue architecture.

Viral Persistence, Recrudescence, and the Importance of the Bone Marrow Niche

One of the most significant, and historically underappreciated, epidemiological features of mousepox is the capacity for ECTV to establish a persistent, non-productive infection that can reactivate upon immunosuppression. This phenomenon has profound implications for the interpretation of experimental results and for the maintenance of specific-pathogen-free (SPF) colonies. Early work suggested that orthopoxviruses cause only acute infections, but rigorous investigation using sensitive PCR-based detection demonstrated that low levels of ECTV genomes persist in tissues, particularly in the bone marrow and blood, for at least 25 weeks post-infection in susceptible mouse strains such as A/J and BALB/c [25].

This persistence is not a latent state in the classical sense; rather, it is a dynamic equilibrium where small amounts of virus or viral genomes are held in check by a continuously active CD8+ T cell response. The immunodominance hierarchy of the antiviral T cell response shifts during this period, indicating ongoing immune engagement with persisting antigen [25]. Critically, when mice that had apparently recovered from acute mousepox were subjected to sustained immunosuppression with cyclophosphamide, they succumbed to a fulminant, lethal infection with high titers of infectious virus detected in multiple organs. Even more alarming from an epidemiological standpoint, these immunosuppressed index mice transmitted the reactivated virus to and caused disease in co-housed naive sentinels [25].

This finding upends the classical view of mousepox as a straightforward, self-limiting disease. It demonstrates that the bone marrow can serve as a long-term viral reservoir, and that any host immune perturbation, whether from experimental manipulation, co-infection, stress, or aging, can lead to recrudescence and reintroduction of the virus into a colony. The host genetic background is a powerful modulator of this risk; disease-resistant C57BL/6 mice showed no evidence of persistence under normal conditions, yet even they could be induced to generate high viral titers in multiple tissues following cyclophosphamide treatment [25]. This suggests that the potential for persistence is a function of the initial host-pathogen interaction, and that "resistance" may represent a more efficient clearance of the primary infection rather than an absolute inability to harbor the virus long-term.

Genetic Determinants of Susceptibility and Their Epidemiological Consequences

The epidemiology of mousepox is profoundly shaped by the genetic makeup of the host population. This is most dramatically illustrated by the stark contrast between resistant mouse strains (e.g., C57BL/6, which survive footpad infection without clinical disease) and susceptible strains (e.g., BALB/c, A/J, DBA/2, which exhibit high morbidity and mortality). The basis for this differential susceptibility is polygenic, involving loci that control the kinetics and magnitude of the innate immune response, particularly the interferon system. Resistance to lethal mousepox strictly requires a functional Type I interferon receptor (IFNAR) on natural killer (NK) cells and monocytes, but not on adaptive immune cells or parenchymal cells such as hepatocytes [10]. This highlights the primacy of the early innate response: IFNAR signaling in NK cells is required for their cytolytic function, while IFNAR signaling in monocytes drives a positive feedback loop to amplify IFN-I production and curtail virus dissemination [10].

The downstream sensing of ECTV is critically dependent on the cGAS-STING pathway. Mice deficient in cGAS or STING exhibit lower levels of type I IFNs, higher viral loads, and increased susceptibility to lethal mousepox [13]. The DNA sensor cGAS is required specifically in bone marrow-derived cells; however, the therapeutic administration of its product, the cyclic dinucleotide cGAMP, can bypass the need for cGAS and rescue otherwise susceptible mice, but only if downstream IRF7 signaling remains intact [12]. These molecular requirements create a complex landscape of permissiveness and resistance that dictates how an outbreak will unfold in a genetically diverse population. In a laboratory setting where inbred strains are housed, an outbreak in a colony of C57BL/6 mice may remain largely subclinical, hidden from routine observation, while the same virus in a BALB/c colony would trigger massive mortality.

Age is another critical epidemiological variable, compounding the effects of host genetics. Aged C57BL/6 mice lose their natural resistance to ECTV, succumbing to infection due to a failure of the early innate response in the draining lymph node. Specifically, aged mice exhibit a defect in the trafficking of migratory dendritic cells (mDCs) from the skin to the draining lymph node [33]. This results in a blunted cascade: reduced IFN-γ production by group 1 innate lymphoid cells, impaired accumulation of inflammatory monocytes, and ultimately, deficient NK cell recruitment [33]. The loss of this early NK cell response, which normally restricts viral spread from the local lymph node, allows ECTV to disseminate systemically in what would otherwise be a resistant host. This age-related susceptibility has direct relevance for colony management, as older breeding stock or retired breeders may become unexpected sources of viral amplification and transmission.

Implications for Colony Management and Biosecurity

The epidemiological profile of ECTV, its environmental stability, multiple transmission routes, capacity for persistence in the bone marrow, and the potential for recrudescence following immunosuppression, necessitates stringent biosecurity protocols for laboratory mouse colonies. Standard practices include the use of individually ventilated cages (IVCs) to minimize aerosol spread, rigorous health monitoring programs using sentinel animals and PCR-based surveillance of exhaust air dust, and the quarantine or testing of all incoming biological materials. The demonstration that virus can be transmitted from a persister mouse to naive co-housed animals following immunosuppression is a stark warning against the use of cyclophosphamide or other immunosuppressive regimens in mice with unknown infection status [25]. Furthermore, the recognition that resistant strains like C57BL/6 can harbor reactivatable virus underscores the inadequacy of using clinical signs alone as a surveillance tool. Routine serological screening for ECTV-specific antibodies remains the cornerstone of colony health monitoring, as seroconversion is a sensitive indicator of past or ongoing infection, even in the absence of overt disease [32].

In conclusion, the epidemiology and transmission of mousepox are dictated by a combination of robust viral mechanisms for direct cell-to-cell spread and systemic dissemination, a stable virion capable of environmental persistence, and a finely balanced host-pathogen interaction that is heavily influenced by mouse genetics, age, and immune status. The discovery of bone marrow persistence and reactivation transforms our understanding of ECTV from a strictly acute pathogen to one capable of long-term maintenance within a population, with the ever-present risk of recrudescence. This complexity makes the mousepox model not only a powerful tool for understanding orthopoxvirus pathogenesis but also a cautionary tale for the management of high-containment laboratory animal facilities.

Diagnostics and Laboratory Detection of Ectromelia Virus

The laboratory diagnosis of ectromelia virus (ECTV) infection is fundamental to both experimental mousepox research and to the management of outbreaks in laboratory rodent colonies. As the causative agent of mousepox, a disease that closely mirrors human smallpox in its pathogenesis, clinical progression, and host immune response, ECTV serves as a critical surrogate model for orthopoxvirus countermeasure development [6, 22, 32]. Consequently, diagnostic and detection methodologies for ECTV must be robust, sensitive, and capable of distinguishing infection from other murine pathogens while also providing quantitative data for viral kinetics, pathogenesis studies, and therapeutic efficacy trials. The diagnostic toolkit for ECTV encompasses classical virological techniques, modern molecular amplification methods, serological assays, and advanced imaging modalities, each with specific applications that reflect the virus’s unique biology and its interactions with host cellular machinery. Importantly, the selection of appropriate diagnostic techniques must account for the viral replication cycle, the tissue tropism, the stage of infection, and the immune status of the host, as ECTV encodes numerous immunomodulatory proteins that can profoundly influence detection outcomes.

Clinical Diagnosis and Sample Collection

Initial suspicion of ECTV infection in a mouse colony arises from clinical signs including lethargy, cutaneous rash, facial edema, conjunctivitis, and, in susceptible strains, rapid mortality [6, 22]. However, clinical diagnosis alone is insufficient due to overlap with other murine pathogens and the variable disease course dictated by mouse genetic background [29, 38]. The collection of appropriate specimens is critical: for early detection, swabs from oropharyngeal and conjunctival sites, skin lesion scrapings, and blood (for viremia detection) are recommended. In terminal or severe cases, tissue samples from spleen, liver, and draining lymph nodes provide the highest viral loads [22, 25]. The bone marrow has been identified as a key site of viral persistence, even in mice that have apparently recovered from acute infection, necessitating inclusion of bone marrow aspirates in investigations of latency or recrudescence [25]. All sample collection must be performed under appropriate biosafety containment (BSL-2 or BSL-3, depending on local regulations) because ECTV, though mouse-specific, is a close relative of variola and monkeypox viruses and serves as a model for human orthopoxvirus disease [9, 32].

Virus Isolation and Plaque Assay

Virus isolation remains a gold-standard method for definitive ECTV detection, providing infectious virus that can be characterized phenotypically and genotypically. ECTV propagates efficiently in several permissive cell lines, including Vero E6, BS-C-1, L929 murine fibroblasts, and RAW 264.7 murine macrophages [5, 17, 21]. The plaque assay is the conventional method for quantification of infectious viral particles. Monolayers of Vero or BS-C-1 cells are inoculated with serial dilutions of clinical or experimental samples, overlayed with semisolid medium, and incubated for 2–4 days. Plaques are visualized by crystal violet or neutral red staining [17, 22]. Importantly, the plaque morphology of ECTV can be influenced by the viral strain and the host cell type; for instance, ECTV Moscow strain produces distinct plaques in L929 cells, while the Naval and Cornell isolates exhibit similar kinetics in Vero cells [26]. The cytopathic effect of ECTV includes cell rounding, detachment, and, notably, the formation of multinucleated giant cells (syncytia) under neutral pH conditions, a phenomenon that distinguishes ECTV from vaccinia virus, which typically requires acidification for syncytium induction [40]. This spontaneous cell-cell fusion is mediated by viral particles accumulating on the plasma membrane and is not blocked by the A56/K2 fusion inhibitory complex, a feature that can be exploited diagnostically in cell culture [40].

Viral isolation also enables the generation of recombinant viruses for research. A transient dominant selection method has been adapted for ECTV to generate deletion mutants without exogenous marker DNA, facilitating studies of virulence genes such as vCD30 and C15 [23, 43]. The growth characteristics of ECTV in macrophages differ between virulent and attenuated strains, with virulent strains replicating more efficiently in peritoneal macrophages ex vivo [44]. This differential growth can be used to assess the virulence phenotype of field isolates or engineered mutants.

Molecular Detection: PCR, qPCR, and Genomic Sequencing

Polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR) have become indispensable for the sensitive and specific detection of ECTV DNA. These methods target conserved orthopoxvirus genes, such as the E9L (DNA polymerase) or B2R (p28) loci, with ECTV-specific primers designed to discriminate it from other orthopoxviruses [22, 41]. In the BALB/c intranasal mousepox model, qPCR can detect viral genomes in blood as early as 4.5 days post-infection and in spleen and liver by 3.5 days, closely paralleling infectious virus titers as measured by plaque assay [22]. The high sensitivity of qPCR is crucial for detecting persistent low-level viral genomes in bone marrow and blood of convalescent mice; indeed, ECTV genomes have been detected by qPCR in these sites up to 25 weeks post-infection in susceptible mouse strains [25]. Importantly, the presence of viral DNA does not always correlate with infectious virus, but it provides evidence of viral persistence that can be reactivated upon immunosuppression [25].

The complete genome sequences of several ECTV strains, Moscow, Naval, Cornell, and the erythromelalgia-related poxvirus (ERPV), have been determined using next-generation sequencing platforms (454-Roche, Illumina, Sanger) [26, 28]. These sequences reveal 98.2–99.8% nucleotide identity among strains, with small deletions and point mutations distinguishing isolates [26, 28]. Whole-genome sequencing is invaluable for outbreak investigations, tracking viral evolution, and identifying genetic determinants of virulence. For instance, the p28 gene (B2R) is required for efficient genome replication in peritoneal macrophages of susceptible A strain mice at low multiplicity of infection, and its deletion impairs viral DNA replication and late gene expression in a cell-type- and MOI-dependent manner [41]. Sequencing also enables the detection of recombination events during construction of recombinant ECTV, ensuring the genetic integrity of mutant viruses [43].

Reverse transcription-PCR (RT-PCR) can be applied to detect viral mRNA transcripts, providing insight into gene expression dynamics. ECTV early genes are expressed within 2–4 hours post-infection, while late gene expression commences after genome replication [15, 21]. The accumulation of double-stranded RNA (dsRNA) during infection is lower in ECTV compared to vaccinia virus, a finding attributed to reduced transcriptional read-through and lower overall mRNA abundance, which may be a strategy to evade PKR-mediated host defenses despite lacking an intact K3L gene [21]. These transcriptional differences have implications for molecular diagnostics: assays targeting late genes may be less sensitive if infection is abortive or if early stages are being examined.

Serological Detection: ELISA, Neutralization, Western Blot, and Immunofluorescence

Serological assays detect host antibodies against ECTV and are particularly useful for surveillance of mouse colonies, retrospective confirmation of infection, and evaluation of vaccine-induced immunity. Enzyme-linked immunosorbent assay (ELISA) using whole-virus lysate or recombinant ECTV proteins (e.g., A33, B5, L1, D8) is commonly employed to measure IgG and IgM responses [6, 27]. In mice vaccinated with modified vaccinia virus Ankara (MVA), ELISA titers correlate with protection against ECTV challenge [30, 31]. The neutralization assay measures the ability of serum antibodies to block infection of permissive cells. Plaque reduction neutralization test (PRNT) is the standard method, but it requires live virus and appropriate biosafety containment. For ECTV, neutralizing antibodies are typically directed against envelope proteins involved in entry, and their titers are often lower than total binding antibodies measured by ELISA [31].

Western blotting provides a confirmatory tool, allowing detection of antibodies against specific viral polypeptides. ECTV-infected cell lysates or purified virions are separated by SDS-PAGE, transferred to membranes, and probed with test sera [6]. This method can distinguish between antibodies to early and late proteins, providing temporal information about infection. Immunofluorescence assay (IFA) using ECTV-infected Vero or L929 cells fixed on slides is a sensitive alternative; serum antibodies bind to viral antigens within fixed cells and are visualized with fluorophore-conjugated secondary antibodies [6, 8]. IFA can also be used to detect viral antigens directly in infected tissues, as demonstrated with confocal imaging of NK cell–infected cell contacts in draining lymph nodes [8]. Quantitative immunofluorescence imaging has revealed that the ECTV virulence factor C15 limits NK cell contact and degranulation, underscoring the utility of imaging-based serological methods for functional studies [8].

One challenge in serological diagnosis of ECTV is the profound immunosuppression induced by the virus. Infection of dendritic cells and macrophages leads to downregulation of major histocompatibility complex (MHC) molecules, costimulatory molecules, and cytokine/chemokine production, which compromises the induction of adaptive immune responses [20, 38]. In GM-CSF–derived bone marrow cells (comprising conventional dendritic cells and macrophages), ECTV infection impairs antigen uptake and processing, inhibits NF-κB and IRF3/7 nuclear translocation, and downregulates cathepsins B, L, and S as well as cystatins [20, 35]. This functional paralysis of antigen-presenting cells results in diminished T-cell proliferation and reduced antibody responses [38]. Therefore, in acutely infected animals, serological tests may yield false negatives if performed too early, before seroconversion, or if the host is severely immunosuppressed. In resistant C57BL/6 mice, however, a robust Th1/Tc1 response develops with IFN-γ and IL-2 production, enabling earlier antibody detection [29].

Advanced Detection Methods: Flow Cytometry, Imaging, and Gene Expression Analysis

Flow cytometry offers a high-throughput approach to quantify ECTV-infected cells and to characterize the host immune response. Intracellular staining for viral antigens (e.g., using polyclonal anti-ECTV sera or monoclonal antibodies against the E3L protein) combined with cell surface markers allows precise identification of infected cell types [8, 33]. In the draining popliteal lymph node of footpad-infected mice, flow cytometry has defined a cascade of innate immune activation: migratory dendritic cells (mDCs) traffic from the skin, produce CCL2/CCL7 to recruit inflammatory monocytes, which in turn secrete CXCL9 to recruit NK cells [33]. ECTV infection of NK cells can be detected by intracellular staining for viral proteins and degranulation markers (CD107a) [8]. Flow cytometry is also used to assess apoptosis and mitochondrial membrane potential in infected cells. ECTV infection leads to mitochondrial network fragmentation, loss of membrane potential, and increased reactive oxygen species (ROS) in both L929 fibroblasts and RAW 264.7 macrophages [1, 14]. These mitochondrial changes can be monitored with dyes such as MitoTracker, tetramethylrhodamine ethyl ester (TMRE), and MitoSOX, providing a functional readout of infection-induced cellular stress [14].

Confocal and electron microscopy are essential for visualizing viral factories, the sites of DNA replication and virus assembly within the cytoplasm. Immunofluorescence labeling of viral cores (e.g., with anti-D8 or anti-A4 antibodies) along with cellular markers has revealed that early in infection, mitochondria cluster around viral factories, and later, fragmented mitochondria co-localize with progeny virions and long actin-based protrusions involved in cell-to-cell spread [14, 19]. These “cytoplasmic corridors” contain straight tubulin filaments, punctate mitochondria, and “cytoplasmic packets” that harbor nascent virions, providing morphological hallmarks of productive ECTV infection [19]. Moreover, ECTV alters the organization of the microtubule cytoskeleton, inducing loss of the microtubule organizing center and increased α-tubulin acetylation, which facilitates intracellular transport of viral particles [37]. Such ultrastructural changes can be detected by transmission electron microscopy or high-resolution confocal microscopy, serving as diagnostic indicators of active viral replication.

Gene expression profiling using quantitative RT-PCR arrays or RNA sequencing has elucidated the host transcriptional response to ECTV. Studies of 84 innate immunity-related genes in peritoneal macrophages from BALB/c and C57BL/6 mice showed a generalized downregulation of pattern recognition receptors, signaling components, and interferon-stimulated genes, except for type I interferon genes which were surprisingly upregulated [42]. Mitochondria-related genes, including those involved in transport, membrane potential, and apoptosis, are significantly suppressed in macrophages and fibroblasts at late stages of infection, with the sirtuin signaling pathway identified as the top canonical pathway affected [34]. These transcriptomic signatures can be used to differentiate ECTV infection from other viral or bacterial stimuli. The cGAS-STING pathway is critical for type I interferon induction in response to ECTV; knockout of cGAS or STING in macrophages abrogates interferon production and enhances viral replication [12, 13]. Measurement of the second messenger 2′3′-cGAMP or downstream interferon-stimulated genes (e.g., Ifit1, Mx1) by qPCR can therefore serve as an indirect indicator of ECTV sensing [12].

Biosafety Considerations in Diagnostics

ECTV is not a human pathogen, but its close genetic relationship to variola and monkeypox viruses mandates careful biosafety practices in diagnostic laboratories. The World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) classify orthopoxviruses as select agents, and while ECTV is not specifically regulated for human biosecurity, laboratory-acquired infections with mousepox are not a concern. However, because ECTV is used as a surrogate for smallpox countermeasure testing, many institutions require BSL-2 facilities with enhanced personal protective equipment (gloves, lab coats, eye protection) for handling infected cell cultures and tissues [17, 22]. For propagation of high-titer virus stocks or during animal necropsy, BSL-3 precautions are often implemented [32]. The availability of molecular diagnostics (qPCR, sequencing) reduces the need for live virus manipulation in some diagnostic workflows, but virus isolation remains necessary for certain applications, such as antiviral susceptibility testing and generation of recombinant mutants.

Conclusion

The diagnostics and laboratory detection of ectromelia virus is a multifaceted discipline that integrates classical virology, molecular biology, immunology, and advanced imaging. From the initial clinical suspicion in a mouse colony to the definitive identification of viral genomes, antigens, or neutralizing antibodies, each method offers unique advantages and limitations. The profound immunomodulatory capabilities of ECTV, including suppression of dendritic cell maturation, cathepsin inhibition, and manipulation of mitochondrial dynamics, must be carefully considered when interpreting diagnostic results, as they can delay or attenuate host immune responses and affect the sensitivity of serological assays. As the mousepox model continues to be refined for the licensure of orthopoxvirus vaccines and therapeutics under the FDA Animal Efficacy Rule, the robustness and reproducibility of ECTV diagnostics will remain paramount [22, 32]. Future advances in single-cell transcriptomics, digital PCR, and real-time in vivo imaging promise to further enhance our ability to detect and quantify ECTV in its natural host, providing deeper insights into the pathogenesis of this important model virus.

Innate Immune Responses: Guanylate-Binding Proteins and MAVS-Dependent Pathways

The antiviral battleground during ectromelia virus (ECTV) infection is defined by a sophisticated interplay between host-intrinsic immune mechanisms and viral countermeasures. At the heart of this conflict lie two interconnected systems: the mitochondrial antiviral signaling (MAVS)-dependent pathway, which serves as a central hub for RIG-I-like receptor (RLR) signaling and is critically influenced by mitochondrial network dynamics, and the guanylate-binding proteins (GBPs), a family of interferon-stimulated genes (ISGs) with potent, yet incompletely understood, anti-poxviral activities. The host strives to detect ECTV replication and propagate type I interferon (IFN-I) signals, while the virus has evolved multiple strategies to dismantle these defenses at the level of organelle function and protein stability.

Mitochondrial Antiviral Signaling and the Orchestration of the Innate Response

Mitochondria are not merely cellular powerhouses; they are pivotal signaling platforms that integrate metabolic status with innate immune activation. The adaptor protein MAVS, anchored to the mitochondrial outer membrane, is the essential downstream effector of the cytosolic RNA sensors RIG-I and MDA5. While ECTV is a large double-stranded DNA virus, the production of double-stranded RNA (dsRNA) intermediates during its replication cycle, a consequence of convergent transcription from opposing viral genes, is a potent trigger for these RLRs [21]. Activation of MAVS leads to the recruitment of signaling complexes that ultimately activate interferon regulatory factor 3 (IRF3) and NF-κB, culminating in the robust expression of type I IFNs and pro-inflammatory cytokines. Critically, this signaling cascade is exquisitely sensitive to the architecture of the mitochondrial network. Research using the L929 murine fibroblast model has demonstrated that ECTV infection profoundly alters mitochondrial morphology, shifting the network from a tubular, interconnected state to a highly fragmented, punctate configuration during the later stages of infection [14]. This fragmentation is not a passive bystander effect; it is a deliberate viral strategy to attenuate host immunity.

A groundbreaking study by Gregorczyk-Zboroch et al. (2024) rigorously dissected the functional consequences of these morphological changes using chemical modulators. Treatment with Mdivi-1, a mitochondrial division inhibitor that promotes an elongated, hyperfused network, was shown to attenuate the suppression of MAVS-dependent immunity by ECTV. In cells with an elongated mitochondrial network, the virus’s ability to dampen downstream signaling was compromised, leading to reduced viral replication compared to infected, unmodulated controls [1]. Conversely, induction of mitochondrial fragmentation using the protonophore carbonyl cyanide m-chlorophenyl hydrazone (CCCP) produced a paradoxical outcome. While fragmented mitochondria were associated with a reduction in the number of progeny virions, this was accompanied by a more profound inhibition of the virus-induced immune response [1]. This suggests that while extensive mitochondrial fragmentation may physically constrain the replication niche, it simultaneously dismantles the MAVS signaling platform, creating an environment where even the diminished viral load experiences less immune pressure. The implication is stark: ECTV actively drives mitochondrial fragmentation not as a side effect of replication, but as a primary mechanism to sever the MAVS-dependent signaling axis, effectively blinding the host cell to the infection. This is further supported by transcriptomic analysis of ECTV-infected fibroblasts and macrophages, which reveals a significant downregulation of genes controlling mitochondrial transport, inner membrane translocation, and membrane polarization during late infection, alongside a cell-type-specific alteration in energy metabolism genes [34]. The disruption of the mitochondrial network is so severe that it includes the relocalization of mitochondria to encircle viral factories early in infection and their subsequent decoration of progeny virions, suggesting a potential role in transporting viral components or providing membrane components for viral envelope formation [14, 19]. This subjugation of mitochondrial physiology effectively cripples the MAVS-dependent signaling node, contributing to the broad immunosuppression observed in infected dendritic cells and macrophages [20, 38].

Guanylate-Binding Proteins: A Specialized Antiviral Arsenal and the Viral Counter-Offensive

If MAVS represents the sensor and signaling hub, GBPs constitute a powerful downstream effector arm of the IFN-mediated antiviral state. These large GTPases are among the most highly expressed ISGs and exert their inhibitory effects against a wide range of intracellular pathogens, including RNA viruses. However, their role against DNA viruses, particularly poxviruses, remained largely unexplored until recently. Groundbreaking work by Gao et al. (2023) has established that murine guanylate-binding protein 2 (GBP2) is a potent restriction factor for ECTV. Overexpression of GBP2 suppressed ECTV replication in a dose-dependent manner, while its knockdown via siRNA significantly enhanced viral titers, confirming that endogenous GBP2 represents a physiologically relevant barrier to infection [2]. The antiviral activity is strictly dependent on the N-terminal GTPase domain; a point mutant deficient in GTP binding (GBP2K51A) completely lost its ability to inhibit ECTV, underscoring the mechanistic requirement for nucleotide binding and hydrolysis [2]. This places GBP2 as a critical component of the early innate defense, acting as a downstream effector of the IFN-I signaling that is itself triggered by the cGAS-STING pathway in response to ECTV DNA [13].

Given the potency of this host factor, it is unsurprising that ECTV, like all successful pathogens, has evolved a dedicated antagonist. A subsequent study by the same group identified the viral poly(A) polymerase catalytic subunit (PAPL) as the specific countermeasure [3]. Through a combination of immunoprecipitation/mass spectrometry (IP/MS) and co-immunoprecipitation (co-IP) assays, PAPL was shown to physically interact with GBP2. The functional consequence of this interaction is the targeted reduction of GBP2 protein levels, a mechanism that effectively neutralizes the antiviral effector [3]. The necessity of this antagonism for viral fitness is demonstrated by the fact that a recombinant ECTV lacking the PAPL gene (generated via CRISPR/Cas9) is severely replication-defective, highlighting the indispensable role of PAPL in overcoming GBP2-mediated restriction [3]. This constitutes a clear example of a molecular arms race: the host deploys GBP2 as a broad-spectrum ISG, and ECTV responds by evolving a specific virulence factor that degrades or destabilizes this protein to restore the replicative niche.

Convergence of Pathways and Immunomodulation

The MAVS and GBP pathways are ultimately linked through the broader type I interferon (IFN-I) response. The activation of MAVS, along with the DNA-sensing cGAS-STING pathway, is essential for the initial burst of IFN-I that drives the expression of ISGs such as Gbp2 [10, 12, 13]. The critical requirement for this axis is underscored by studies showing that mice deficient in cGAS, STING, or the downstream transcription factor IRF7 are exquisitely sensitive to lethal mousepox [12, 13]. Furthermore, the primary source of this protective IFN-I appears to be hematopoietic cells, specifically natural killer (NK) cells and monocytes, rather than the target parenchymal cells like hepatocytes [10]. This paracrine signaling loop is essential for NK cell cytolytic function and monocyte-mediated containment of the virus within the draining lymph node [8, 10, 33].

This entire interdependent system is ruthlessly targeted by ECTV. The virus not only fragments mitochondria to inhibit MAVS [1, 14] but also encodes a suite of additional immunomodulators that suppress the upstream detection and downstream amplification of these signals. For instance, the ECTV C15 protein limits contact between NK cells and infected cells, inhibiting degranulation and thus dampening the very effector cells that require IFNAR signaling [8, 23]. Simultaneously, the virus suppresses the expression of cathepsins in dendritic cells, impairing antigen processing and further crippling the adaptive arm of the immune response that relies on initial innate sensing [35, 39]. In this context, GBP2 emerges as a critical, but not solitary, line of defense that the virus must breach. The targeted degradation of GBP2 by PAPL is a testament to the efficacy of this host factor, as the virus has invested in a specific antagonist to maintain its replicative capacity. The failure of the innate system to contain ECTV in susceptible mouse strains is therefore a multifactorial collapse, involving the sabotaging of mitochondrial signaling platforms, the direct neutralization of ISG effectors like GBP2, and the paralysis of professional antigen-presenting cells [3, 14, 20, 34, 38]. Understanding these detailed molecular interactions provides a roadmap for developing therapeutic strategies that could stabilize MAVS signaling or protect GBPs from viral antagonism, thereby restoring the host's intrinsic ability to control orthopoxvirus infection.

Viral Immune Evasion Strategies: The Role of Poly(A) Polymerase Catalytic Subunit

The capacity of orthopoxviruses to establish productive infections within immunocompetent hosts is fundamentally predicated upon their extensive arsenal of immunomodulatory proteins. These viral host-response modifiers systematically dismantle the host’s antiviral signaling cascades, cytokine networks, and effector cell functions. Among the myriad of virulence factors encoded by the ectromelia virus (ECTV) genome, the poly(A) polymerase catalytic subunit (PAPL) has recently emerged as a critical, yet previously underappreciated, antagonist of the interferon-stimulated gene (ISG) response. The identification of PAPL as a direct countermeasure to guanylate-binding protein 2 (GBP2) represents a paradigm shift in our understanding of how ECTV subverts the intrinsic antiviral state, revealing a sophisticated molecular arms race at the level of individual protein–protein interactions [3].

The Interferon-Stimulated Gene Landscape and the Emergence of GBP2 as an Antiviral Effector

To fully appreciate the strategic importance of PAPL, one must first contextualize the antiviral environment it is designed to neutralize. Type I interferons (IFN-I) are the cornerstone of the innate antiviral response, signaling through the ubiquitous IFN-I receptor (IFNAR) to induce the transcription of hundreds of ISGs that collectively establish an antiviral state [10]. The critical nature of this pathway in ECTV resistance is underscored by the observation that C57BL/6 mice broadly deficient in IFNAR succumb rapidly to infection, whereas wild-type mice survive without disease. Notably, the protective effect of IFNAR signaling is exquisitely cell-type specific, being required in natural killer (NK) cells and monocytes, but not in adaptive immune cells or parenchymal hepatocytes, which are principal targets of ECTV [10]. This demonstrates that the innate, rather than adaptive, compartment is the primary battleground for early viral containment.

Within this IFN-I-driven milieu, guanylate-binding proteins (GBPs) constitute a family of large GTPases that are among the most highly expressed ISGs. While extensively studied in the context of RNA viruses and intracellular bacteria, their role in DNA virus restriction, particularly poxviruses, has only recently been elucidated. Gao et al. (2023) provided the first definitive evidence that GBP2 exerts a significant, dose-dependent inhibitory effect on ECTV replication [2]. This restriction is mechanistically dependent on the N-terminal GTPase activity of GBP2, as a GTP-binding-impaired mutant (GBP2K51A) completely abrogated the antiviral effect [2]. The precise mechanism by which GBP2 restricts ECTV remains an area of active investigation, but it likely involves the disruption of viral replication complex assembly, interference with membrane dynamics during viral morphogenesis, or direct targeting of viral components. The critical point is that GBP2 represents a potent, IFN-inducible barrier that ECTV must overcome to replicate efficiently.

PAPL: A Viral Countermeasure Targeting GBP2 Stability

The discovery of PAPL as a GBP2-interacting protein was a direct consequence of the observation that while GBP2 inhibits ECTV, the inhibition is only “mild but statistically significant” [3]. This suggested that ECTV likely encodes a specific antagonist to neutralize GBP2. Using a combination of immunoprecipitation coupled with mass spectrometry (IP/MS) and co-immunoprecipitation (co-IP) assays, Gao et al. (2023) identified the ECTV-encoded poly(A) polymerase catalytic subunit (PAPL) as the viral protein that physically associates with GBP2 [3].

This finding is particularly striking because the canonical function of PAPL in poxvirus biology is the post-transcriptional polyadenylation of viral mRNA, a process essential for mRNA stability and translation. However, the interaction with GBP2 reveals a moonlighting function for PAPL as a dedicated immune evasion protein. The functional consequence of this interaction is profound: PAPL antagonizes the antiviral activity of GBP2 by reducing its steady-state protein levels [3]. While the precise degradative mechanism, whether via proteasomal degradation, lysosomal targeting, or inhibition of translation, remains to be fully characterized, the net effect is a depletion of the host’s antiviral effector. This strategy is a hallmark of poxviral pathogenesis: co-opting a core replication enzyme to simultaneously perform a non-replicative, immunomodulatory function.

The Essentiality of PAPL for Viral Replication and Pathogenesis

The biological significance of PAPL extends beyond its role as a simple GBP2 antagonist. Genetic ablation of the PAPL gene using the CRISPR/Cas9 system produced a recombinant ECTV (ECTVΔPAPL) that exhibited a significantly diminished replication capacity compared to the wild-type virus [3]. This finding is critical for two reasons. First, it demonstrates that PAPL is indispensable for the ECTV replication cycle, likely due to its primary function in mRNA polyadenylation. Second, it suggests that the immune evasion function of PAPL (GBP2 degradation) is not merely ancillary but is integrated into the virus’s core replicative strategy. A virus lacking PAPL cannot replicate efficiently, even in the absence of a robust GBP2 response, because it cannot properly process its own transcripts.

This dual essentiality, required for both basic replication and immune evasion, positions PAPL as a high-value target for therapeutic intervention. The observation that ECTVΔPAPL is severely attenuated aligns with the broader principle that poxviruses cannot afford to lose genes that simultaneously serve replicative and immunomodulatory roles. This is in stark contrast to purely non-essential immunomodulators, such as the viral CD30 homolog (vCD30), whose deletion does not impair mousepox-induced fatality in vivo [43]. The essential nature of PAPL suggests that any antiviral strategy designed to inhibit its function would simultaneously cripple viral replication and restore the host’s GBP2-mediated antiviral state.

Broader Implications for Poxviral Immune Evasion and Host Range

The PAPL-GBP2 axis must be viewed within the larger context of ECTV’s multi-layered immune evasion strategy. ECTV employs a staggering array of mechanisms to disable the host response, including: the inhibition of NK cell contact by the C15 virulence factor [8]; the suppression of cathepsin and cystatin expression in dendritic cells to impair antigen processing [35, 39]; the modulation of mitochondrial network morphology to attenuate MAVS-dependent signaling [1]; and the antagonism of the cGAS-STING DNA sensing pathway [12, 13]. The discovery of PAPL adds a new dimension to this repertoire by targeting the effector phase of the IFN response, rather than the sensing or signaling phases.

Furthermore, the interaction between PAPL and GBP2 may have implications for poxvirus host range and species tropism. GBP2 is a highly conserved ISG across mammals, and the ability of a viral PAPL to effectively degrade it could be a determinant of whether a poxvirus can productively infect a given host species. The fact that ECTV, a mouse-specific pathogen, has evolved a dedicated mechanism to neutralize murine GBP2 suggests that similar interactions may exist for other orthopoxviruses in their respective hosts. For instance, the monkeypox virus, which has recently emerged as a significant global health threat, encodes its own PAPL homolog. Understanding whether the monkeypox virus PAPL can similarly antagonize human GBP2 could provide critical insights into its pathogenesis and zoonotic potential. The World Health Organization (WHO) has highlighted the urgent need for research into monkeypox virus immunobiology, and the PAPL-GBP2 interaction represents a promising avenue for such investigations.

In summary, the poly(A) polymerase catalytic subunit of ECTV is far more than a simple housekeeping enzyme. It is a bifunctional virulence factor that couples an essential role in viral mRNA processing with a dedicated immune evasion function directed against the GBP2 antiviral effector. By directly binding and reducing GBP2 protein levels, PAPL effectively disarms a key component of the interferon-induced antiviral state, allowing ECTV to replicate and disseminate within its natural host. The essential nature of PAPL for viral replication underscores its potential as a target for novel antiviral therapeutics, and its study provides a compelling model for understanding the molecular arms race between poxviruses and the mammalian innate immune system.

Preclinical Models and Therapeutic Implications

The strategic value of the ectromelia virus (ECTV)-mousepox model as a surrogate for human smallpox and an increasingly relevant platform for emerging orthopoxvirus threats, such as monkeypox, is anchored in its remarkable fidelity to the pathogenesis of variola virus (VARV) in a natural host. This system provides a uniquely comprehensive window into host-pathogen dynamics, permitting the rigorous preclinical evaluation of antiviral compounds and immunological interventions that cannot be ethically or practically tested in humans. Under the U.S. Food and Drug Administration’s “Animal Efficacy Rule,” the ECTV model stands as a validated pathway for the licensure of medical countermeasures against orthopoxviruses, accommodating the urgent necessity for therapeutic development in a global landscape marked by waning herd immunity following the cessation of smallpox vaccination [6, 9, 32]. The therapeutic implications of this model extend far beyond simple efficacy testing; they inform the mechanistic understanding of viral spread, immune evasion, and tissue pathology, guiding the rational design of combination therapies that target both the replicating virus and the host’s destructive inflammatory response.

Refining the Preclinical Platform: Strain, Route, and Endpoint

The selection of mouse strain and inoculation route constitutes the foundational decision in any ECTV preclinical study, as these parameters determine disease kinetics, severity, and the very nature of the immune response interrogated. The BALB/c mouse, representing the susceptible phenotype, uniformly succumbs to lethal mousepox following intranasal inoculation with as few as 125 plaque-forming units (PFU) of ECTV, exhibiting a reproducible disease course characterized by primary viremia at 3.5 days post-infection (dpi), detectable virus in spleen and liver by 4.5 dpi, and complete mortality by day 10 [22]. This highly predictable timeline is essential for the consistent evaluation of antiviral efficacy, providing clear endpoints for survival, viral load reduction, and histopathological scoring. In contrast, the C57BL/6 resistant strain models the efficacy of innate immune barriers; these mice survive footpad infection without overt disease, a resistance largely attributable to interferon signaling in specific hematopoietic lineages [10]. The mechanistic dissection of this resistance has illuminated that type I interferon receptor (IFNAR) expression on natural killer (NK) cells and monocytes, but not on adaptive immune cells or parenchymal hepatocytes, is non-negotiable for survival [10]. This finding has profound therapeutic implications, suggesting that prophylactic or early therapeutic strategies should prioritize the augmentation of innate, rather than solely adaptive, antiviral states. The age of the mouse is another critical variable in model design, as aged C57BL/6 mice lose their natural resistance due to a specific defect in dendritic cell (DC) trafficking from the skin to the draining lymph node, resulting in impaired NK cell recruitment [33]. This age-dependent vulnerability mirrors human susceptibility to severe orthopoxvirus disease and provides a stringent model for testing interventions in immunosenescent populations.

The choice of inoculation route, intranasal versus footpad, also dictates the pathophysiology under study. Intranasal infection models aerosol transmission and the development of viral pneumonia, a primary cause of morbidity and mortality in severe orthopoxvirus infections. This model has been instrumental in revealing that antiviral monotherapy, even with potent agents like cidofovir, is ineffective if administered late after symptom onset because lung pathology is driven by an exaggerated, self-sustaining inflammatory response [7]. Conversely, footpad inoculation models the natural route of infection via skin abrasions, emphasizing the critical role of the draining lymph node as a battleground between viral dissemination and the host’s innate immune cascade. Here, the cGAS-STING DNA sensing pathway, activated in bone marrow-derived cells, is an absolute requirement for type I interferon induction and survival; local administration of the STING agonist cGAMP can rescue cGAS-deficient mice, bypassing the proximal sensor yet still requiring downstream IRF7 and IFNAR for full protection [12, 13]. This identifies a distinct therapeutic target: small molecule STING agonists could be deployed to bolster the innate antiviral state even when the initial sensing machinery is compromised by viral antagonism.

Mechanistic Insights Guiding Antiviral and Immunomodulatory Strategies

The therapeutic implications derived from the ECTV model extend far beyond simple measurements of viral titer reduction, delving into the complex molecular choreography of viral replication and immune subversion at the subcellular and systemic levels. ECTV, like other orthopoxviruses, hijacks host cellular machinery for its own benefit, and these points of dependency represent both vulnerabilities and targets for intervention.

Mitochondrial Dynamics and Metabolic Control: The virus’s manipulation of mitochondrial networks is a striking example of host subversion with clear therapeutic potential. During early infection, mitochondria are recruited to viral factories to support energy-demanding replication; later, the network becomes fragmented, and these fragmented mitochondria co-localize with progeny virions, likely providing membrane sources for envelope formation or energy for transport [14]. This manipulation is achieved through the profound downregulation of mitochondria-related genes, including those governing transport, membrane potential, and apoptosis pathways, particularly in macrophages, which may undergo energy collapse [34]. Crucially, experimental modulation of mitochondrial morphology alters viral fitness: forcing an elongated mitochondrial network using the fission inhibitor Mdivi-1 attenuates the virus’s suppression of the MAVS-dependent immune response and reduces ECTV replication in fibroblasts, while a fragmented network also reduces progeny virions but does so by increasing immune inhibition [1]. This suggests that pharmacological agents targeting mitochondrial fission-fusion machinery could be repurposed to tip the balance from a pro-viral to an anti-viral state. The virus further protects its replicative niche by inducing a mitochondrial heat shock response, upregulating Hsp60 and Hsp10 while simultaneously suppressing apoptosis through elevated Bcl-2 and Bcl-xL and reduced Bax, thereby ensuring cell survival for continued viral production [36]. Therapeutics that reverse this anti-apoptotic blockade, potentially in combination with direct antivirals, could force premature cell death, starving the virus of its replicative factory.

Counteracting Viral Immune Evasins: ECTV devotes a substantial portion of its genome to encoding proteins that systematically dismantle the host immune response. The characterization of these virulence factors provides a direct blueprint for therapeutic counter-strategies. For instance, the viral C15 protein, a large membrane protein, simultaneously inhibits CD4+ T cell activation and, critically, limits NK cell contact with infected cells, thereby facilitating early viral spread from the draining lymph node to visceral organs [8, 23]. A recombinant ECTV lacking C15 is significantly attenuated, highlighting this protein as a high-value target for small molecule or antibody-based therapies designed to restore NK cell surveillance. Similarly, the viral protein E163, a secreted chemokine-binding protein, prevents chemokine interaction with glycosaminoglycans (GAGs) on the cell surface, disrupting the formation of chemotactic gradients necessary for immune cell recruitment [18]. Understanding the structural basis of E163’s GAG-binding activity allows for the rational design of decoy molecules that could outcompete the viral protein and restore normal immune trafficking.

The arms race between host restriction factors and viral antagonists is another rich vein of therapeutic insight. Guanylate-binding protein 2 (GBP2), an interferon-stimulated gene, exerts a GTPase-dependent anti-ECTV effect; its overexpression suppresses viral replication while its knockdown enhances infection [2]. Unsurprisingly, ECTV has evolved a countermeasure: the viral poly(A) polymerase catalytic subunit (PAPL) directly interacts with GBP2 and antagonizes its antiviral activity by reducing GBP2 protein levels [3]. A CRISPR/Cas9-mediated knockout of PAPL renders ECTV replication-deficient, underscoring its essential nature and validating it as a potential drug target. A GBP2-stabilizing or PAPL-inhibiting molecule could restore this intrinsic antiviral pathway.

Reversing the Functional Paralysis of Antigen-Presenting Cells: ECTV has evolved a sophisticated strategy to paralyze dendritic cells and macrophages, the lynchpins of the adaptive immune response. The virus suppresses the expression of cathepsins (B, L, S) and their endogenous inhibitors (cystatins B, C), impairing the endosomal processing of antigens for MHC class II presentation [35, 39]. It also downregulates the expression of MHC and costimulatory molecules (CD80/86), rendering DCs unable to stimulate CD4+ T cell proliferation [20, 38]. Disruption of both canonical and noncanonical NF-κB signaling further abrogates the production of proinflammatory cytokines (TNF, IL-6, IL-12) and chemokines necessary for Th1 polarization, while simultaneously upregulating IL-10, a potent immunosuppressive cytokine [20, 38, 45]. The downstream consequence is a shift from a protective Th1 response to a non-protective Th2 profile, which is a hallmark of susceptibility in BALB/c mice [29]. Therapeutics designed to restore DC function, perhaps through TLR agonists that can bypass the viral blockade, or by inhibiting the viral proteases responsible for cathepsin degradation, could reawaken the adaptive immune response even in the face of established infection.

Combination Therapy: The Paradigm for Treating Viral Pneumonia

Perhaps the most clinically translatable insight from the ECTV model is the demonstration that effective treatment of viral pneumonia requires a dual-pronged strategy targeting both the replicating virus and the host’s dysregulated inflammatory response. The landmark study by Pandey et al. [7] provides the mechanistic and therapeutic framework for this paradigm. In a lethal respiratory ECTV model, treatment with the antiviral cidofovir alone after the onset of clinical signs effectively reduced lung viral load but failed to prevent mortality, as animals succumbed to severe immunopathology driven by unmitigated inflammation. Conversely, treatment with etanercept, a TNF-neutralizing fusion protein, had no effect on viral replication but significantly dampened levels of multiple proinflammatory cytokines (TNF, IL-6, IL-1β, IL-12p40, TGF-β, CCL5) and dampened activation of the STAT3 signaling pathway. The combination of cidofovir and etanercept dramatically improved clinical disease, reduced lung pathology, and fully protected mice from mortality, even when treatment was initiated after symptoms were apparent [7]. This work highlights a critical therapeutic principle: tissue damage in viral pneumonia is a product of both viral cytopathy and the host’s inflammatory storm. This finding has direct relevance to the treatment of severe human orthopoxvirus infections and even extends conceptually to other respiratory viral diseases, including seasonal influenza and SARS-CoV-2. The study further demonstrated that direct targeting of the STAT3 signaling pathway with a specific inhibitor in combination with cidofovir was similarly effective, providing an alternative strategy for patients who may not tolerate TNF blockade [7].

Antiviral and Vaccine Prophylaxis in the Preclinical Context

The ECTV model has been the primary workbench for evaluating the efficacy and safety of the current orthopoxvirus antiviral arsenal, including cidofovir, brincidofovir (CMX001), and tecovirimat (ST-246) [6, 32]. These studies have defined the therapeutic window, route of administration, and dose-response relationships necessary for advancing these drugs toward human use. For example, brincidofovir, an orally bioavailable lipid conjugate of cidofovir, has been shown to be compatible with concurrent vaccination. Co-administration of BCV with the live attenuated smallpox vaccine (Dryvax or ACAM2000) reduced the severity of vaccination-associated lesions without compromising the development of full protective immunity against subsequent lethal ECTV challenge [27]. This finding has significant public health implications, as it suggests a strategy for combining vaccination with antiviral prophylaxis in a bioterrorism scenario, particularly for individuals with contraindications to vaccination or uncertain exposure status, allowing for safer mass immunization campaigns.

The model has also been essential for assessing the safety and immunogenicity of next-generation vaccines. A critical virulence factor for ECTV is the E3L gene, encoding a double-stranded RNA-binding protein that antagonizes the host PKR and RNase L pathways [15, 21]. An ECTV mutant lacking the E3L gene (ECTVΔE3L) is completely replication-defective and nonpathogenic in susceptible BALB/c mice, yet it induces robust protective immunity against wild-type virus challenge [15]. This principle has been extended to the development of safer human vaccines; a vaccinia virus strain (NYCBH) deleted for the E3L gene is highly attenuated in a newborn mouse model yet fully protects mice against lethal ECTV challenge, eliciting protective antibody levels comparable to the parental vaccine strain [31]. The modified vaccinia virus Ankara (MVA), already licensed as a smallpox and monkeypox vaccine, has been engineered using synthetic reverse genetics systems, and rescued MVA viruses have been shown to trigger robust immune responses and protect mice against lethal ECTV attack [30]. The ECTV model thus serves as a stringent heterologous challenge system for validating the protective capacity of novel poxvirus vaccines.

If ECTV were to extend its host range or if related orthopoxviruses like monkeypox become more established in non-endemic regions, the implications for global health security would be profound. The World Health Organization (WHO) and national public health agencies would need to rely heavily on the preclinical data generated from the ECTV-mousepox model to guide the deployment of existing countermeasures and to accelerate the licensure of new ones under the Animal Rule. The model has already provided the first evidence that ECTV can persist in the bone marrow and blood of recovered mice and can be reactivated by immunosuppression, leading to transmission to naïve animals [25]. This finding of viral persistence, even in a resistant host like the C57BL/6 mouse, raises significant cautionary flags for the potential of long-term virus survival in human survivors and the risk of recrudescence, a factor that must be considered in any post-exposure prophylaxis or cure strategy.

References

[1] Gregorczyk-Zboroch K, Szulc-Dąbrowska L, Pruchniak P, Gieryńska M, Mielcarska M, Biernacka Z, et al.. Modifications of Mitochondrial Network Morphology Affect the MAVS-Dependent Immune Response in L929 Murine Fibroblasts during Ectromelia Virus Infection. Pathogens. 2024. DOI: https://doi.org/10.3390/pathogens13090717

[2] Gao Z, Meng Z, He X, Chen G, Fang Y, Tian H, et al.. Guanylate-Binding Protein 2 Exerts GTPase-Dependent Anti-Ectromelia Virus Effect. Microorganisms. 2023. DOI: https://doi.org/10.3390/microorganisms11092258

[3] Gao Z, He X, Chen G, Fang Y, Meng Z, Tian H, et al.. The Viral Protein Poly(A) Polymerase Catalytic Subunit Interacts with Guanylate-Binding Proteins 2 to Antagonize the Antiviral Ability of Targeting Ectromelia Virus. International Journal of Molecular Sciences. 2023. DOI: https://doi.org/10.3390/ijms242115750

[4] Biernacka Z, Gregorczyk-Zboroch K, Lasocka I, Ostrowska A, Struzik J, Gieryńska M, et al.. Ectromelia Virus Affects the Formation and Spatial Organization of Adhesive Structures in Murine Dendritic Cells In Vitro. International Journal of Molecular Sciences. 2023. DOI: https://doi.org/10.3390/ijms25010558

[5] Teplyakova TE, Kabanov AS, Ovchinnikova A, Odnoshevskyh DA, Petrovskaya IF, Nepomnyashchikh TS, et al.. [Screening of antiviral activity of samples from chaga Inonotus obliquus and humic acid from brown coal on Vero cell culture against ectromelia virus (Poxviridae: Orthopoxvirus; ECTV)].. Voprosy virusologii. 2023. DOI: https://doi.org/10.36233/0507-4088-174

[6] Iheukwumere I, Iheukwumere C, Unaeze BU, Ike VE, Nnadozie HC, Onyema SO. Mousepox Virus (Ectromelia Virus), Molecular Mechanisms, Clinical Manifestations, and Control Strategies. IPS Journal of Basic and Clinical Medicine. 2023. DOI: https://doi.org/10.54117/ijbcm.v2i4.22

[7] Pandey P, Rumaih ZA, Kels MJT, Ng E, Kc R, Chaudhri G, et al.. Targeting ectromelia virus and TNF/NF-κB or STAT3 signaling for effective treatment of viral pneumonia. Proceedings of the National Academy of Sciences of the United States of America. 2022. DOI: https://doi.org/10.1073/pnas.2112725119

[8] Peauroi EM, Carro SD, Pei L, Reynoso GV, Hickman H, Eisenlohr L. The ectromelia virus virulence factor C15 facilitates early viral spread by inhibiting NK cell contact. iScience. 2022. DOI: https://doi.org/10.1016/j.isci.2022.105510

[9] . ectromelia virus. CABI Compendium. 2022. DOI: https://doi.org/10.1079/cabicompendium.96100

[10] Melo-Silva CR, Alves-Peixoto P, Heath N, Tang L, Montoya B, Knudson CJ, et al.. Resistance to lethal ectromelia virus infection requires Type I interferon receptor in natural killer cells and monocytes but not in adaptive immune or parenchymal cells. PLoS Pathogens. 2021. DOI: https://doi.org/10.1371/journal.ppat.1009593

[11] Morgis RA, Haan K, Schrey JM, Zimmerman R, Hersperger AR. The epidermal growth factor ortholog of ectromelia virus activates EGFR/ErbB1 and demonstrates mitogenic function in vitro.. Virology. 2021. DOI: https://doi.org/10.1016/j.virol.2021.09.003

[12] Wong EB, Montoya B, Ferez M, Stotesbury C, Sigal L. Resistance to ectromelia virus infection requires cGAS in bone marrow-derived cells which can be bypassed with cGAMP therapy. PLoS Pathogens. 2019. DOI: https://doi.org/10.1371/journal.ppat.1008239

[13] Cheng W, He X, Jia H, Chen G, Jin Q, Long Z, et al.. The cGas–Sting Signaling Pathway Is Required for the Innate Immune Response Against Ectromelia Virus. Frontiers in Immunology. 2018. DOI: https://doi.org/10.3389/fimmu.2018.01297

[14] Gregorczyk K, Wyżewski Z, Szczepanowska J, Toka F, Mielcarska M, Bossowska-Nowicka M, et al.. Ectromelia Virus Affects Mitochondrial Network Morphology, Distribution, and Physiology in Murine Fibroblasts and Macrophage Cell Line. Viruses. 2018. DOI: https://doi.org/10.3390/v10050266

[15] Frey TR, Forsyth KS, Sheehan MM, DeHaven BC, Pevarnik JG, Hand ES, et al.. Ectromelia virus lacking the E3L ortholog is replication-defective and nonpathogenic but does induce protective immunity in a mouse strain susceptible to lethal mousepox. Virology. 2018. DOI: https://doi.org/10.1016/j.virol.2018.03.016

[16] Duncan ML, Horsington J, Eldi P, Rumaih ZA, Karupiah G, Newsome TP. Loss of Actin-Based Motility Impairs Ectromelia Virus Release In Vitro but Is Not Critical to Spread In Vivo. Viruses. 2018. DOI: https://doi.org/10.3390/v10030111

[17] Chaudhri G, Kaladimou G, Pandey P, Karupiah G. Propagation and Purification of Ectromelia Virus. Current Protocols in Microbiology. 2018. DOI: https://doi.org/10.1002/cpmc.65

[18] Heidarieh H, Alcamí A. Mechanism of action of the viral chemokine-binding protein E163 from ectromelia virus. Journal of Biological Chemistry. 2018. DOI: https://doi.org/10.1074/jbc.RA118.004432

[19] Szulc-Dąbrowska L, Gregorczyk-Zboroch K, Struzik J, Wyżewski Z, Ostrowska A, Toka F, et al.. Long actin-based cellular protrusions as novel evidence of the cytopathic effect induced in immune cells infected by the ectromelia virus. Central European Journal of Immunology. 2018. DOI: https://doi.org/10.5114/ceji.2018.81352

[20] Szulc-Dąbrowska L, Struzik J, Ostrowska A, Guzera M, Toka F, Bossowska-Nowicka M, et al.. Functional paralysis of GM-CSF–derived bone marrow cells productively infected with ectromelia virus. PLoS ONE. 2017. DOI: https://doi.org/10.1371/journal.pone.0179166

[21] Frey TR, Lehmann MH, Ryan C, Pizzorno M, Sutter G, Hersperger AR. Ectromelia virus accumulates less double-stranded RNA compared to vaccinia virus in BS-C-1 cells. Virology. 2017. DOI: https://doi.org/10.1016/j.virol.2017.06.010

[22] Garver J, Weber L, Vela E, Anderson M, Warren R, Merchlinsky M, et al.. Ectromelia Virus Disease Characterization in the BALB/c Mouse: A Surrogate Model for Assessment of Smallpox Medical Countermeasures. Viruses. 2016. DOI: https://doi.org/10.3390/v8070203

[23] Reynolds S, Earl P, Minai M, Moore IN, Moss B. A homolog of the variola virus B22 membrane protein contributes to ectromelia virus pathogenicity in the mouse footpad model. Virology. 2016. DOI: https://doi.org/10.1016/j.virol.2016.11.010

[24] Hand ES, Haller SL, Peng C, Rothenburg S, Hersperger AR. Ectopic Expression of Vaccinia Virus E3 and K3 Cannot Rescue Ectromelia Virus Replication in Rabbit RK13 Cells. PLoS ONE. 2015. DOI: https://doi.org/10.1371/journal.pone.0119189

[25] Sakala IG, Chaudhri G, Scalzo A, Eldi P, Newsome TP, Buller R, et al.. Evidence for Persistence of Ectromelia Virus in Inbred Mice, Recrudescence Following Immunosuppression and Transmission to Naïve Mice. PLoS Pathogens. 2015. DOI: https://doi.org/10.1371/journal.ppat.1005342

[26] Mavian C, López-Bueno A, Bryant N, Seeger K, Quail M, Harris D, et al.. The genome sequence of ectromelia virus Naval and Cornell isolates from outbreaks in North America. Virology. 2014. DOI: https://doi.org/10.1016/j.virol.2014.06.010

[27] Parker S, Crump R, Foster S, Hartzler H, Hembrador E, Lanier E, et al.. Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus. Antiviral Research. 2014. DOI: https://doi.org/10.1016/j.antiviral.2014.08.003

[28] Mendez-Rios JD, Martens C, Bruno D, Porcella S, Zheng Z, Moss B. Genome Sequence of Erythromelalgia-Related Poxvirus Identifies it as an Ectromelia Virus Strain. PLoS ONE. 2012. DOI: https://doi.org/10.1371/journal.pone.0034604

[29] Szulc L, Gieryńska M, Winnicka A, Martyniszyn L, Boratyńska-Jasińska A, Niemiałtowski M. T cell cytokine synthesis at the single-cell level in BALB/c and C57BL/6 mice infected with ectromelia virus.. Postępy Higieny i Medycyny Doświadczalnej. 2012. DOI: https://doi.org/10.5604/17322693.991606

[30] Gao Z, Wang B, Liu T, Zhao Z, Xu J, Zhao X, et al.. Design and construction of a fast synthetic modified vaccinia virus Ankara reverse genetics system for advancing vaccine development. Frontiers in Microbiology. 2025. DOI: https://doi.org/10.3389/fmicb.2025.1572706

[31] Denzler K, Schriewer JM, Parker S, Werner C, Hartzler H, Hembrador E, et al.. The attenuated NYCBH vaccinia virus deleted for the immune evasion gene, E3L, completely protects mice against heterologous challenge with ectromelia virus. Vaccine. 2011. DOI: https://doi.org/10.1016/j.vaccine.2011.09.108

[32] Parker S, Siddiqui A, Painter G, Schriewer JM, Buller R. Ectromelia Virus Infections of Mice as a Model to Support the Licensure of Anti-Orthopoxvirus Therapeutics. Viruses. 2010. DOI: https://doi.org/10.3390/v2091918

[33] Stotesbury C, Wong EB, Tang L, Montoya B, Knudson CJ, Melo-Silva CR, et al.. Defective early innate immune response to ectromelia virus in the draining lymph nodes of aged mice due to impaired dendritic cell accumulation. Aging Cell. 2020. DOI: https://doi.org/10.1111/acel.13170

[34] Szulc-Dąbrowska L, Wyżewski Z, Gregorczyk-Zboroch K, Toka F, Szczepanowska J, Struzik J, et al.. Mitochondria-related gene expression profiles in murine fibroblasts and macrophages during later stages of ectromelia virus infection in vitro.. Acta virologica. 2020. DOI: https://doi.org/10.4149/av_2020_305

[35] Bossowska-Nowicka M, Mielcarska M, Romaniewicz M, Kaczmarek M, Gregorczyk-Zboroch K, Struzik J, et al.. Ectromelia virus suppresses expression of cathepsins and cystatins in conventional dendritic cells to efficiently execute the replication process. BMC Microbiology. 2019. DOI: https://doi.org/10.1186/s12866-019-1471-1

[36] Wyżewski Z, Gregorczyk-Zboroch K, Mielcarska M, Bossowska-Nowicka M, Struzik J, Szczepanowska J, et al.. Mitochondrial Heat Shock Response Induced by Ectromelia Virus is Accompanied by Reduced Apoptotic Potential in Murine L929 Fibroblasts. Archivum Immunologiae et Therapiae Experimentalis. 2019. DOI: https://doi.org/10.1007/s00005-019-00554-5

[37] Szulc-Dąbrowska L, Palusiński M, Struzik J, Gregorczyk-Zboroch K, Toka F, Schollenberger A, et al.. Ectromelia virus induces tubulin cytoskeletal rearrangement in immune cells accompanied by a loss of the microtubule organizing center and increased α-tubulin acetylation. Archives of Virology. 2018. DOI: https://doi.org/10.1007/s00705-018-4030-4

[38] Szulc-Dąbrowska L, Struzik J, Cymerys J, Winnicka A, Nowak Z, Toka F, et al.. The in Vitro Inhibitory Effect of Ectromelia Virus Infection on Innate and Adaptive Immune Properties of GM-CSF-Derived Bone Marrow Cells Is Mouse Strain-Independent. Frontiers in Microbiology. 2017. DOI: https://doi.org/10.3389/fmicb.2017.02539

[39] Bossowska-Nowicka M, Mielcarska M, Kaczmarek M, Romaniewicz M, Struzik J, Toka F, et al.. Ectromelia virus suppresses cathepsins and cystatins expression at both mRNA and protein levels in dendritic cells. Journal of Immunology. 2018. DOI: https://doi.org/10.4049/jimmunol.200.supp.126.21

[40] Erez N, Paran N, Maik-Rachline G, Politi B, Israely T, Schnider P, et al.. Induction of cell-cell fusion by ectromelia virus is not inhibited by its fusion inhibitory complex. Virology Journal. 2009. DOI: https://doi.org/10.1186/1743-422X-6-151

[41] Dong J, Paszkowski P, Kocíncová D, Ingham R. Complete deletion of Ectromelia virus p28 impairs virus genome replication in a mouse strain, cell type, and multiplicity of infection-dependent manner. Virus Research. 2022. DOI: https://doi.org/10.1016/j.virusres.2022.198968

[42] Toka F, Dolega P, Mielcarska M, Bossowska M. Comparison of messenger RNA expression profile of antiviral innate immune response genes in peritoneal macrophages from BALB/c and C57BL/6 mice infected with ectromelia virus (INM3P.413). Journal of Immunology. 2015. DOI: https://doi.org/10.4049/jimmunol.194.supp.127.18

[43] Alejo A, Saraiva M, Ruiz-Argüello M, Viejo-Borbolla A, Marco MFd, Salguero F, et al.. A Method for the Generation of Ectromelia Virus (ECTV) Recombinants: In Vivo Analysis of ECTV vCD30 Deletion Mutants. PLoS ONE. 2009. DOI: https://doi.org/10.1371/journal.pone.0005175

[44] Roberts J. GROWTH OF VIRULENT AND ATTENUATED ECTROMELIA VIRUS IN CULTURED MACROPHAGES FROM NORMAL AND ECTROMELIAIMMUNE MICE.. Journal of Immunology. 1964. DOI: https://doi.org/10.4049/jimmunol.92.6.837

[45] Struzik J, Szulc-Dąbrowska L, Mielcarska M, Bossowska-Nowicka M, Koper M, Gieryńska M. First Insight into the Modulation of Noncanonical NF-κB Signaling Components by Poxviruses in Established Immune-Derived Cell Lines: An In Vitro Model of Ectromelia Virus Infection. Pathogens. 2020. DOI: https://doi.org/10.3390/pathogens9100814